Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y12 inhibitor.

Yi-Fan ZhangXiaoxue ZhuYan ZhanXiaojiao LiCai LiuYunting ZhuHong ZhangHaijing WeiYu XiaHongbin SunYongqiang LiuXiaojuan LaiYanchun GongXuefang LiuYongguo LiYanhua DingDafang Zhong

Published in: British journal of clinical pharmacology (2020)

CYP2C19 polymorphisms have less impact on vicagrel as compared to clopidogrel. Drug exposure and response to vicagrel in PMs were even higher than to clopidogrel in IMs.

Keyphrases

acute coronary syndrome
percutaneous coronary intervention
antiplatelet therapy
escherichia coli
cell migration
pseudomonas aeruginosa
cell adhesion